AI Engines For more Details: Perplexity Kagi Labs You
Antiseptic Properties: Merbromin exhibits strong antiseptic properties due to its active ingredient, merbromin, which is a mercury-containing compound. When applied to minor wounds, cuts, or scrapes, merbromin helps prevent infection by killing or inhibiting the growth of bacteria, fungi, and other microorganisms on the skin's surface.
Topical Antimicrobial: Merbromin is effective against a wide range of bacteria and fungi commonly found on the skin. It is commonly used to disinfect and clean minor wounds, cuts, and abrasions to prevent infection and promote healing.
Wound Healing: By preventing infection and promoting a clean wound environment, merbromin can aid in the natural healing process of minor skin injuries. It helps reduce the risk of complications and allows the skin to regenerate and repair itself more efficiently.
First Aid: Merbromin is a popular choice for first aid kits and is often used for the initial treatment of minor injuries at home, in schools, or in healthcare settings. It provides a convenient and effective means of disinfecting wounds before further medical attention if needed.
Staining Effect: One notable characteristic of merbromin is its vivid red-orange color. While this staining effect can help visualize the area where it has been applied, it may also stain clothing, skin, and other surfaces. Users should take care to avoid contact with fabrics and delicate materials.
Safety Considerations: Merbromin contains mercury, which raises concerns about its safety, particularly with prolonged or excessive use. While merbromin is generally considered safe for short-term topical use on intact skin, it should not be ingested or applied to large areas of broken skin. Additionally, individuals with known allergies to mercury or mercury-containing compounds should avoid using merbromin.
Availability: Merbromin is available in various formulations, including solutions, tinctures, and ointments, under different brand names such as Mercurochrome, Medichrom, and others. It is typically applied directly to the affected area using a cotton swab or applicator.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.3 | 0.03 |
| Allergies | 7.3 | 4.1 | 0.78 |
| Allergy to milk products | 2.6 | 1.6 | 0.63 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.3 | 8.3 | -0.14 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.1 | 1.5 | 1.73 |
| Ankylosing spondylitis | 5.1 | 1.8 | 1.83 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 2.1 | 0.3 | 6 |
| Asthma | 6.5 | 3.2 | 1.03 |
| Atherosclerosis | 2.7 | 2.2 | 0.23 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.7 | 11.7 | 0 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 3 | 3 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 1.2 | 1.2 | |
| Cancer (General) | 0.9 | 2.9 | -2.22 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.6 | 4.1 | -0.14 |
| Cerebral Palsy | 1.7 | 1.3 | 0.31 |
| Chronic Fatigue Syndrome | 6.6 | 7.7 | -0.17 |
| Chronic Kidney Disease | 5.2 | 3.2 | 0.63 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 3 | 2 | 0.5 |
| Chronic Urticaria (Hives) | 2 | 1.8 | 0.11 |
| Coagulation / Micro clot triggering bacteria | 1.9 | 1.3 | 0.46 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.7 | 2.8 | 2.11 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 3 | 3 | 0 |
| COVID-19 | 12.1 | 14.7 | -0.21 |
| Crohn's Disease | 10.2 | 6.7 | 0.52 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.2 | 1.9 | -0.58 |
| d-lactic acidosis (one form of brain fog) | 0.6 | 0.6 | |
| deep vein thrombosis | 3 | 1.4 | 1.14 |
| Denture Wearers Oral Shifts | 2.1 | 2.1 | |
| Depression | 13.3 | 10.9 | 0.22 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.6 | -0.13 |
| Endometriosis | 3.5 | 2.6 | 0.35 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.3 | 2.6 | 0.65 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.9 | 4.9 | 0.41 |
| gallstone disease (gsd) | 4.3 | 1.4 | 2.07 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.7 | 2.3 | 0.61 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.4 | 0.8 | 2 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.4 | -1.67 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.2 | 2 | 1.1 |
| Heart Failure | 5.4 | 2.2 | 1.45 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.9 | 0.6 | 2.17 |
| hypercholesterolemia (High Cholesterol) | 1.1 | 0.6 | 0.83 |
| hyperglycemia | 3 | 2 | 0.5 |
| Hyperlipidemia (High Blood Fats) | 1.2 | 0.3 | 3 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.6 | 6.6 | -0.18 |
| Hypothyroidism | 0.3 | 1 | -2.33 |
| Hypoxia | 3.9 | 0.3 | 12 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.7 | 11.9 | -0.11 |
| Insomnia | 2.5 | 3.3 | -0.32 |
| Intelligence | 2 | 0.6 | 2.33 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 9.8 | 6.2 | 0.58 |
| ischemic stroke | 3.2 | 1.7 | 0.88 |
| Liver Cirrhosis | 9 | 5.7 | 0.58 |
| Long COVID | 8.5 | 9.1 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.8 | 1.63 |
| Metabolic Syndrome | 9.3 | 9.4 | -0.01 |
| Mood Disorders | 13.3 | 8.8 | 0.51 |
| multiple chemical sensitivity [MCS] | 1.5 | 0.1 | 14 |
| Multiple Sclerosis | 8.8 | 7 | 0.26 |
| Multiple system atrophy (MSA) | 2.1 | 0.7 | 2 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.4 | -10.33 |
| Neuropathy (all types) | 1 | 2.2 | -1.2 |
| neuropsychiatric disorders (PANDAS, PANS) | 1.2 | 1.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.5 | 5.7 | 0.14 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.6 | 9.9 | 0.27 |
| obsessive-compulsive disorder | 7 | 4.8 | 0.46 |
| Osteoarthritis | 3.3 | 1.5 | 1.2 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 10.4 | 8.3 | 0.25 |
| Polycystic ovary syndrome | 7.9 | 3.5 | 1.26 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4.2 | 3.9 | 0.08 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.4 | 4.7 | 1 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.4 | 1.29 |
| scoliosis | 0.9 | 1.2 | -0.33 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.5 | 0.3 | 4 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 2.2 | 0.6 | 2.67 |
| Stress / posttraumatic stress disorder | 3.5 | 3.3 | 0.06 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.2 | 0.3 | 3 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 10.2 | 8.8 | 0.16 |
| Ulcerative colitis | 7 | 8.6 | -0.23 |
| Unhealthy Ageing | 6.8 | 2.7 | 1.52 |
| Vitiligo | 2.5 | 1.8 | 0.39 |
